Representatives of BCCOP, Osteoporosis Canada and MedAccess BC, have continued to advocate with the BC Ministry of Health to review PharmaCare criteria to enhance coverage of osteoporosis treatment.
BC PharmaCare has approved an open listing for alendronate and risedronate for all patients. This means physicians will no longer require filling SA forms for these agents.
Primary prevention for patients on aromatase inhibitor therapies will still qualify for denosumab coverage after filling a Special Authority form.
In addition, a denosumab biosimilar (Jubbonti) will be covered through the current denosumab stipulations. There will be funding support for pharmacists and providers (through MSP) to assist patients through this transition see details on website.
Comments